A phase I multi-center, open-label, single-dose escalation clinical trial of VTLS-589 [del-1 gene therapy] for treatment of patients with peripheral arterial disease

Trial Profile

A phase I multi-center, open-label, single-dose escalation clinical trial of VTLS-589 [del-1 gene therapy] for treatment of patients with peripheral arterial disease

Completed
Phase of Trial: Phase I

Latest Information Update: 02 Feb 2006

At a glance

  • Drugs Del-1 gene therapy; VLTS 934
  • Indications Intermittent claudication; Peripheral arterial disorders
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms DELTA
  • Most Recent Events

    • 02 Feb 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top